New regulatory developments in both the US and Europe are promoting a radical change to accelerate the approval of new medications for rare disease. These include the 21st Century Cure Act in the US and the Adaptive Regulatory Pathway in Europe.
This webinar will discuss how real world evidence is playing a larger role across the entire product life cycle, with a focus on late phase regulatory discussions and payer decision-making.
Join us as we discuss an approach to evidence-generation strategies in drug and medical device development that enables integrated teams to develop and implement targeted and effective value propositions.
Get a deeper understanding of the changing contracting landscape and to learn ways to leverage innovative approaches to improve the commercial success of your biopharmaceutical products.
